

EQA6 TEST FORMS

Test form – *Escherichia coli* panel

Which method did you primarily use for antimicrobial susceptibility testing of *Escherichia coli* in this EQA?

- MIC – Microbroth dilution
- MIC – Macro dilution (tubes)
- MIC – Agar dilution
- Gradient test
- Disk diffusion
- Tablets – Neo Sensitabs, Rosco

Please note: You will be able to change method for each individual antibiotic in the IT module.

Which standard(s)/guideline(s) did you use when performing AST?

- CLSI
- EUCAST
- ISO20776-1:2019
- TREK
- Other

Which incubation conditions did you use?

_____ °C/_____ h

Comments or additional information:

Test form – *Escherichia coli* Ec EQAsia 23.1

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation		
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R
Ec EQAsia 23.1 Identification <input type="checkbox"/> <i>Escherichia coli</i> <input type="checkbox"/> Non- <i>Escherichia coli</i> <input type="checkbox"/> Not tested	Amikacin, AMK			
	Ampicillin, AMP			
	Azithromycin, AZI			
	Cefepime, FEP			
	Cefotaxime, FOT			
	Cefotaxime, FOT + clavulanic acid			
	Cefoxitin, FOX			
	Ceftazidime, TAZ			
	Ceftazidime, TAZ + clavulanic acid			
	Chloramphenicol, CHL			
	Ciprofloxacin, CIP			
	Colistin, COL			
	Doripenem, DOR			
	Ertapenem, ETP			
	Gentamicin, GEN			
	Imipenem, IMI			
	Levofloxacin, LEVO			
	Meropenem, MERO			
	Nalidixic acid, NAL			
	Piperacillin/tazobactam, PT4			
	Sulfamethoxazole, SMX			
	Tetracycline, TET			
	Tigecycline, TGC			
	Tobramycin, TOB			
	Trimethoprim, TMP			
	Trimethoprim/sulfamethoxazole, SXT			

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?

- Yes
 No

Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?

- Yes
 No

Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]

- ESBL-phenotype
 ESBL+AmpC-phenotype
 AmpC-phenotype
 Carbapenemase-phenotype
 Other phenotype

Test form – *Escherichia coli* Ec EQAsia 23.2

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation		
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R
Ec EQAsia 23.2	Amikacin, AMK			
	Ampicillin, AMP			
Identification	Azithromycin, AZI			
	Cefepime, FEP			
<input type="checkbox"/> <i>Escherichia coli</i>	Cefotaxime, FOT			
	Cefotaxime, FOT + clavulanic acid			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Cefoxitin, FOX			
	Ceftazidime, TAZ			
<input type="checkbox"/> Not tested	Ceftazidime, TAZ + clavulanic acid			
	Chloramphenicol, CHL			
	Ciprofloxacin, CIP			
	Colistin, COL			
	Doripenem, DOR			
	Ertapenem, ETP			
	Gentamicin, GEN			
	Imipenem, IMI			
	Levofloxacin, LEVO			
	Meropenem, MERO			
	Nalidixic acid, NAL			
	Piperacillin/tazobactam, PT4			
	Sulfamethoxazole, SMX			
	Tetracycline, TET			
	Tigecycline, TGC			
	Tobramycin, TOB			
	Trimethoprim, TMP			
	Trimethoprim/sulfamethoxazole, SXT			

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?

Yes

No

Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?

Yes

No

Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]

ESBL-phenotype

ESBL+AmpC-phenotype

AmpC-phenotype

Carbapenemase-phenotype

Other phenotype

Test form – *Escherichia coli* Ec EQAsia 23.3

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation			
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R	
Ec EQAsia 23.3	Amikacin, AMK				
	Ampicillin, AMP				
Identification	Azithromycin, AZI				
	Cefepime, FEP				
	Cefotaxime, FOT				
	<input type="checkbox"/> <i>Escherichia coli</i>	Cefotaxime, FOT + clavulanic acid			
	<input type="checkbox"/> Non- <i>Escherichia coli</i>	Cefoxitin, FOX			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Ceftazidime, TAZ				
	Ceftazidime, TAZ + clavulanic acid				
<input type="checkbox"/> Not tested	Chloramphenicol, CHL				
	Ciprofloxacin, CIP				
	Colistin, COL				
	Doripenem, DOR				
	Ertapenem, ETP				
	Gentamicin, GEN				
	Imipenem, IMI				
	Levofloxacin, LEVO				
	Meropenem, MERO				
	Nalidixic acid, NAL				
	Piperacillin/tazobactam, PT4				
	Sulfamethoxazole, SMX				
	Tetracycline, TET				
	Tigecycline, TGC				
	Tobramycin, TOB				
	Trimethoprim, TMP				
	Trimethoprim/sulfamethoxazole, SXT				

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

<p>Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]</p> <p><input type="checkbox"/> ESBL-phenotype</p> <p><input type="checkbox"/> ESBL+AmpC-phenotype</p> <p><input type="checkbox"/> AmpC-phenotype</p> <p><input type="checkbox"/> Carbapenemase-phenotype</p> <p><input type="checkbox"/> Other phenotype</p>
--

Test form – *Escherichia coli* Ec EQAsia 23.4

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation		
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R
Ec EQAsia 23.4	Amikacin, AMK			
	Ampicillin, AMP			
Identification	Azithromycin, AZI			
	Cefepime, FEP			
<input type="checkbox"/> <i>Escherichia coli</i>	Cefotaxime, FOT			
	Cefotaxime, FOT + clavulanic acid			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Cefoxitin, FOX			
	Ceftazidime, TAZ			
<input type="checkbox"/> Not tested	Ceftazidime, TAZ + clavulanic acid			
	Chloramphenicol, CHL			
	Ciprofloxacin, CIP			
	Colistin, COL			
	Doripenem, DOR			
	Ertapenem, ETP			
	Gentamicin, GEN			
	Imipenem, IMI			
	Levofloxacin, LEVO			
	Meropenem, MERO			
	Nalidixic acid, NAL			
	Piperacillin/tazobactam, PT4			
	Sulfamethoxazole, SMX			
	Tetracycline, TET			
	Tigecycline, TGC			
	Tobramycin, TOB			
	Trimethoprim, TMP			
	Trimethoprim/sulfamethoxazole, SXT			

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?

Yes

No

Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?

Yes

No

Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]

ESBL-phenotype

ESBL+AmpC-phenotype

AmpC-phenotype

Carbapenemase-phenotype

Other phenotype

Test form – *Escherichia coli* Ec EQAsia 23.5

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation		
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R
Ec EQAsia 23.5	Amikacin, AMK			
	Ampicillin, AMP			
Identification	Azithromycin, AZI			
	Cefepime, FEP			
<input type="checkbox"/> <i>Escherichia coli</i>	Cefotaxime, FOT			
	Cefotaxime, FOT + clavulanic acid			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Cefoxitin, FOX			
	Ceftazidime, TAZ			
<input type="checkbox"/> Not tested	Ceftazidime, TAZ + clavulanic acid			
	Chloramphenicol, CHL			
	Ciprofloxacin, CIP			
	Colistin, COL			
	Doripenem, DOR			
	Ertapenem, ETP			
	Gentamicin, GEN			
	Imipenem, IMI			
	Levofloxacin, LEVO			
	Meropenem, MERO			
	Nalidixic acid, NAL			
	Piperacillin/tazobactam, PT4			
	Sulfamethoxazole, SMX			
	Tetracycline, TET			
	Tigecycline, TGC			
	Tobramycin, TOB			
	Trimethoprim, TMP			
	Trimethoprim/sulfamethoxazole, SXT			

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

<p>Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]</p> <p><input type="checkbox"/> ESBL-phenotype</p> <p><input type="checkbox"/> ESBL+AmpC-phenotype</p> <p><input type="checkbox"/> AmpC-phenotype</p> <p><input type="checkbox"/> Carbapenemase-phenotype</p> <p><input type="checkbox"/> Other phenotype</p>
--

Test form – *Escherichia coli* Ec EQAsia 23.6

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation			
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R	
Ec EQAsia 23.6	Amikacin, AMK				
	Ampicillin, AMP				
Identification	Azithromycin, AZI				
	Cefepime, FEP				
	Cefotaxime, FOT				
	<input type="checkbox"/> <i>Escherichia coli</i>	Cefotaxime, FOT + clavulanic acid			
	<input type="checkbox"/> Non- <i>Escherichia coli</i>	Cefoxitin, FOX			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Ceftazidime, TAZ				
	Ceftazidime, TAZ + clavulanic acid				
<input type="checkbox"/> Not tested	Chloramphenicol, CHL				
	Ciprofloxacin, CIP				
	Colistin, COL				
	Doripenem, DOR				
	Ertapenem, ETP				
	Gentamicin, GEN				
	Imipenem, IMI				
	Levofloxacin, LEVO				
	Meropenem, MERO				
	Nalidixic acid, NAL				
	Piperacillin/tazobactam, PT4				
	Sulfamethoxazole, SMX				
	Tetracycline, TET				
	Tigecycline, TGC				
	Tobramycin, TOB				
	Trimethoprim, TMP				
	Trimethoprim/sulfamethoxazole, SXT				

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

<p>Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]</p> <p><input type="checkbox"/> ESBL-phenotype</p> <p><input type="checkbox"/> ESBL+AmpC-phenotype</p> <p><input type="checkbox"/> AmpC-phenotype</p> <p><input type="checkbox"/> Carbapenemase-phenotype</p> <p><input type="checkbox"/> Other phenotype</p>
--

Test form – *Escherichia coli* Ec EQAsia 23.7

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Strain – <i>Escherichia coli</i>	Antimicrobial	Interpretation		
		≤; =; >	MIC-value (mg/L) or Zone diameter (mm)	S/I/R
Ec EQAsia 23.7	Amikacin, AMK			
	Ampicillin, AMP			
Identification	Azithromycin, AZI			
	Cefepime, FEP			
	Cefotaxime, FOT			
	Cefotaxime, FOT + clavulanic acid			
<input type="checkbox"/> <i>Escherichia coli</i>	Cefoxitin, FOX			
<input type="checkbox"/> Non- <i>Escherichia coli</i>	Ceftazidime, TAZ			
	Ceftazidime, TAZ + clavulanic acid			
<input type="checkbox"/> Not tested	Chloramphenicol, CHL			
	Ciprofloxacin, CIP			
	Colistin, COL			
	Doripenem, DOR			
	Ertapenem, ETP			
	Gentamicin, GEN			
	Imipenem, IMI			
	Levofloxacin, LEVO			
	Meropenem, MERO			
	Nalidixic acid, NAL			
	Piperacillin/tazobactam, PT4			
	Sulfamethoxazole, SMX			
	Tetracycline, TET			
	Tigecycline, TGC			
	Tobramycin, TOB			
	Trimethoprim, TMP			
	Trimethoprim/sulfamethoxazole, SXT			

All strains displaying reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol.

Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?

Yes

No

Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?

Yes

No

Please select the detected ESBL-phenotype (see guideline in the EQAS protocol): [please select one option]

ESBL-phenotype

ESBL+AmpC-phenotype

AmpC-phenotype

Carbapenemase-phenotype

Other phenotype

Test form – Reference strain: *Escherichia coli* ATCC 25922/CCM 3954

Strain – <i>Escherichia coli</i> ATCC 25922/ CCM 3954	Antimicrobial	MIC value (mg/L) or Zone Diameter (mm)
	Amikacin, AMK	
	Ampicillin, AMP	
	Azithromycin, AZI	
	Cefepime, FEP	
	Cefotaxime, FOT	
	Cefotaxime, FOT + clavulanic acid	
	Cefoxitin, FOX	
	Ceftazidime, TAZ	
	Ceftazidime, TAZ + clavulanic acid	
	Chloramphenicol, CHL	
	Ciprofloxacin, CIP	
	Doripenem, DOR	
	Ertapenem, ETP	
	Gentamicin, GEN	
	Imipenem, IMI	
	Levofloxacin, LEVO	
	Meropenem, MERO	
	Nalidixic acid, NAL	
	Piperacillin/tazobactam, PT4	
Sulfamethoxazole, SMX		
Tetracycline, TET		
Tigecycline, TGC		
Tobramycin, TOB		
Trimethoprim, TMP		
Trimethoprim/sulfamethoxazole, SXT		

Test form – Reference strain: *Escherichia coli* NCTC 13846/CCM 8874 (for colistin)

Strain – <i>Escherichia coli</i> NCTC 13846/ CCM 8874	Antimicrobial	MIC value (mg/L) or Zone Diameter (mm)
	Colistin, COL	